Correspondence/Findings
Epicrania Fugax is a paroxysmal, short-lasting (1–10 s), head pain moving across one hemicranium, describing a linear or zag trajectory, starting and ending in territories of different nerves [1,2]. At the end of the attacks, ipsilateral autonomic signs such as lacrimation, conjunctival injection or rhinorrhoea may occur. Between attacks, patients are usually free of symptoms. However, we have recently encountered an Epicrania Fugax patient complaining of interictal pain. This finding was not a surprise as interictal pain may be a feature of paroxysmal headaches [3] and trigeminal neuralgia [4].
A 39-year-old female patient complained of one-day-lasting episodes of linear-shaped pain in her right hemicranium. In the past few months she had been suffering from paroxysms of severe pain lasting 5–10 seconds, starting in the posterior parietal area of the right hemicranium and rapidly moving with a lineal trajectory to the internal canthus of the ipsilateral eye. As a rule, once the pain reached the eye, lacrimation ensued. The frequency ranged from 1 to 3 paroxysms daily, in the symptomatic days (2–3/week). In between attacks, the patient felt a continuous, moderate pain, confined to the territory where the motion was perceived. The patient clearly delineated the painful lineal area in her head and could finely draw it, thus giving a definite impression of the localization of such an interictal pain.
Anzeige
Wang Y et al. [5] described headaches with pain episodes localized in a line-shaped area of one hemicranium. Topographically, this description parallels that of our patient. However, the patients of Wang Y et al. did not report moving paroxysms. More evidences are needed before we can decipher the nosologic position of linear headaches, but as far as Epicrania Fugax is concerned, its clinical features may rarely include a linear interictal pain that may even become the main complaint.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JAP: made the clinical observation and wrote the manuscript. PB: contributed to the final draft of the article. Both authors commented on the manuscript and approved the final version of the manuscript.